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Abstract
Zinc finger nucleases (ZFNs) have been used successfully to create genome-specific double-strand breaks and thereby
stimulate gene targeting by several thousand fold. ZFNs are chimeric proteins composed of a specific DNA-binding domain
linked to a non-specific DNA-cleavage domain. By changing key residues in the recognition helix of the specific DNA-
binding domain, one can alter the ZFN binding specificity and thereby change the sequence to which a ZFN pair is being
targeted. For these and other reasons, ZFNs are being pursued as reagents for genome modification, including use in gene
therapy. In order for ZFNs to reach their full potential, it is important to attenuate the cytotoxic effects currently associated
with many ZFNs. Here, we evaluate two potential strategies for reducing toxicity by regulating protein levels. Both
strategies involve creating ZFNs with shortened half-lives and then regulating protein level with small molecules. First, we
destabilize ZFNs by linking a ubiquitin moiety to the N-terminus and regulate ZFN levels using a proteasome inhibitor.
Second, we destabilize ZFNs by linking a modified destabilizing FKBP12 domain to the N-terminus and regulate ZFN levels
by using a small molecule that blocks the destabilization effect of the N-terminal domain. We show that by regulating
protein levels, we can maintain high rates of ZFN-mediated gene targeting while reducing ZFN toxicity.
Citation: Pruett-Miller SM, Reading DW, Porter SN, Porteus MH (2009) Attenuation of Zinc Finger Nuclease Toxicity by Small-Molecule Regulation of Protein
Levels. PLoS Genet 5(2): e1000376. doi:10.1371/journal.pgen.1000376
Editor: Gregory S. Barsh, Stanford University School of Medicine, United States of America
Received July 8, 2008; Accepted January 9, 2009; Published February 13, 2009
Copyright:  2009 Pruett-Miller et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work in the Porteus lab is supported by National Institutes of Health grant R01 HL079295, a Basil O’Connor starter award from the March of Dimes,
a career development award from the Burroughs Welcome Fund, and Texas State funding through University of Texas Southwestern Medical Center. SMPM is
supported by a National Institutes of Health pharmacology training grant at the University of Texas Southwestern Medical Center. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: matthew.porteus@utsouthwestern.edu
Introduction
Homologous recombination is a natural mechanism that cells
use for a variety of processes including double strand break (DSB)
repair [1]. To repair a DSB by homologous recombination, the
cell usually uses the sister chromatid as a donor-template but can
use other pieces of DNA such as extrachromosomal DNA. Gene
targeting uses homologous recombination to make a precise
genomic change and is commonly used experimentally in a variety
of cells including yeast and murine embryonic stem cells.
However, the spontaneous rate of homologous recombination is
too low in mammalian somatic cells (10
26) to be commonly used
experimentally or therapeutically [2–5]. The rate of gene
targeting, however, can be increased (to over 10
22) by creating
a gene specific DSB [2,6–10].
Zinc Finger Nucleases (ZFNs) can create site-specific DSBs and
have been shown to increase the rate of gene targeting by over 5
orders of magnitude [11–13]. ZFNs are chimeric proteins that
consist of a specific DNA binding domain made up of tandem zinc
finger binding motifs fused to a non-specifc cleavage domain from
the FokI restriction endonuclease (the development of which is
reviewed in [14]). By changing key residues in the DNA binding
domain, ZFN binding specificity can be altered providing a
generalized strategy for delivering a site-specific DSB. However,
many ZFNs have been shown to have cytotoxic effects [2,15–17].
Several studies suggest that this toxicity is caused by ‘‘off-target’’
DSBs. For example, a zinc finger protein containing no nuclease
domain was not toxic when transfected into HEK293 cells
(unpublished data). Similarly, Beumer et al. (2006) have shown
that ZFNs containing point mutations to inactivate the nuclease
domain do not exhibit cytotoxicity in flies [18]. There have been
two published strategies for reducing the number of ‘‘off-target’’
breaks: (1) increase the specificity of the ZFN by protein
engineering or (2) force heterodimerization of the ZFN pairs
[16,19–24]. Here, we explore a third strategy to reduce
cytotoxicity by small molecule regulation of ZFN protein levels.
By creating ZFNs from zinc finger DNA binding domains that
are more specific, toxicity is reduced. While on-target cutting is
generated by heterodimerization of a ZFN pair at its target site (at
least 18 base pairs), off-target cutting can be mediated by either
homodimer pairs or heterodimer pairs. Modifications in the
nuclease to prevent homodimerization results in ZFNs with
reduced toxicity [16,20,21]. We found, however, that this
reduction can come at a cost of reduced activity in stimulating
gene targeting [16] (Wilson et al., manuscript submitted).
It has been shown that the rate of gene targeting can be
increased, up to a point, by increasing the amount of transfected
ZFN expression plasmids [16,18]. However, very high levels of
ZFN expression cause toxicity without increasing targeting rates
[16,18]. These observation lead to the hypothesis that reduced
toxicity could also be obtained by being able to regulate ZFN
expression. This ‘‘Goldilocks’’ phenomenon means that being able
PLoS Genetics | www.plosgenetics.org 1 February 2009 | Volume 5 | Issue 2 | e1000376to titrate the amount of ZFN protein is critical to optimizing ZFN
mediated gene targeting.
Porteus and Baltimore demonstrated that maximal DSB-
mediated gene targeting occurs within 60 hours of transfection of
DNA [2]. Expression of ZFNs outside this window will increase
toxicity without increasing targeting. We hypothesized that if we
could narrow the time of ZFN protein expression, we could reduce
toxicity while maintaining high rates of targeting. In this study, we
use two previously described strategies to regulate protein levels and
apply them to ZFNs. We show that by regulating protein levels, we
reduce the number of ‘‘off-target’’ DSBs and reduce toxicity, while
maintaining high ZFN-stimulated gene targeting activity.
Results
Ubiquitin Tagging and the N-End Rule as a Strategy to
Regulate ZFN Protein Levels
The ability to regulate ZFN protein levels could theoretically
give optimal rates of gene targeting with minimal toxicity.
Degradation signals or ‘‘degrons’’ are specific domains that confer
instability on a protein [25]. The N-end rule correlates the in vivo
half-life of a protein to the N-terminal amino acid; some residues
are destabilizing while other residues are stabilizing [26,27].
Normal N-terminal processing precludes simply adding a desired
residue to the N-terminus of a protein. By adding a ubiquitin
moiety (Ub) to the N-terminus of a protein, the N-terminal amino
acid of a protein can be controlled. In eukaryotes, the Ub-X-POI
(where POI is protein of interest) fusion is cleaved by Ub-specific
processing proteases immediately before X (where X is an amino
acid residue) [28]. This cleavage leaves the X residue as the N-
terminal amino acid and thus affects protein stability. It has been
established by several groups that an N-terminal arginine is a
degradation signal [26,28].
It is also possible to create poorly cleavable or uncleavable Ub-
X-POI fusions. If the ubiquitin protein is not cleaved from the
POI, the protein can undergo ubiquitin fusion degradation [29].
That is, the Ub-X-POI fusion can be further ubiquitinated and
thereby ‘‘marked’’ for degradation by the proteasome. This allows
for another strategy to create short-lived POIs. By substituting the
last residue of the ubiquitin moiety from glycine to valine and
using a valine linker (Ub-VV-POI), the ubiquitin moiety can no
longer be cleaved from the POI [28].
We created a pair of Ub-VV-ZFNs and Ub-R-ZFNs fusion
proteins (Figure 1A) to destabilize a pair of previously validated
ZFNs targeting the GFP gene that contained the wildtype FokI
domain [16]. The Ub-VV-ZFNs were made to take advantage of
the potential destabilizing effect of a covalently linked N-terminal
ubiquitin, and the Ub-R-ZFNs were made to take advantage of
the potential destabilizing effect of an N-terminal arginine.
Expression of the ZFN chimeras in transiently transfected
HEK293 cells was examined by Western blot analysis
(Figure 1B). The size of the Ub-VV-ZFNs corresponded with
the expected size of an uncleaved fusion protein. The size of the
Ub-R-ZFNs corresponded with the size of the unmodified ZFNs,
confirming that the ubiquitin moiety was cleaved.
The addition of the proteasome inhibitor MG132 can increase
the levels of Ub-X-POI fusion proteins [28]. We therefore
examined the expression of ubiquitin linked ZFNs and unmodified
ZFNs in the presence and absence of MG132 (Figure 1B). The
addition of the proteasome inhibitor had little effect on the
unmodified ZFNs. In contrast, addition of MG132 to cells
transfected with ubiquitin modified ZFNs produced a striking
increase in the expression relative to the level of expression of the
modified proteins in the absence of MG132. It is interesting to
note that even the untreated Ub-R-ZFNs had an increase in
protein levels relative to the unmodified ZFNs (Figure 1B,
compare Ub-R-ZFNs, +MG132 at 24 hours to unmodified ZFNs
at 24 hours). Although expression of Ub-R-ZFNs is higher than
the unmodified ZFNs, the UB-R-ZFNs levels decrease more
rapidly suggesting that the N-terminus arginine is, in fact,
destabilizing. We hypothesize that the addition of the ubiquitin
moiety to the N-terminus aided in protein folding of the ZFNs and
thus produced higher expression.
We compared the activity of the ubiquitin linked ZFNs to the
unmodified ZFNs using a GFP gene targeting assay. In this assay,
gene targeting is measured by the correction of a chromosomally
integrated mutated GFP target gene [2]. We normalized the gene
targeting rate for each condition to the rate obtained for the
optimal amount of the unmodified ZFNs as previously determined
[16]. We first compared activities of the Ub-VV-ZFNs and Ub-R-
ZFNs with increasing amounts of DNA in the absence of
proteasome inhibitor to that of the unmodified proteins
(Figure 2A and 2B). In the absence of drug, both the Ub-VV-
ZFNs and the Ub-R-ZFNs, at all DNA concentrations tested,
produced lower amounts of gene targeting compared to rates
produced using the unmodified pair. The Ub-VV-ZFNs produced
lower rates of gene targeting in the absence of drug compared to
the Ub-R-ZFNs.
We next evaluated the rate of gene targeting produced by the
Ub-modified proteins in the presence of MG132 compared to
when the drug was absent (Figure 2C and 2D). Both the Ub-VV-
ZFNs and Ub-R-ZFNs produced increased rates of gene targeting
in the presence of MG132 compared to when the drug was absent.
The rate of gene targeting produced by the Ub-VV-ZFNs in the
presence of drug was not as high, however, as rates produced by
the unmodified protein. In contrast, in the presence of drug, the
Ub-R-ZFNs produced equivalent rates of gene targeting as
compared to the unmodified proteins.
In order to determine if the ubiquitin modification of these
ZFNs reduced the cytotoxicity associated with unmodified ZFNs,
we used a flow cytometry based cell survival assay (the ‘‘toxicity
assay’’) [16]. In this assay, we use a non-toxic endonuclease, I-SceI
(hereafter called Sce), as the standard for a non-toxic nuclease to
which we normalize relative amounts of toxicity. The percent of
surviving cells transfected with a potentially toxic nuclease is
compared to the percent of surviving cells transfected with Sce. A
lower percent of surviving cells is a sign of greater toxicity. As
shown in Figure 2E, the percent survival relative to Sce of the
Author Summary
Zinc finger nucleases (ZFNs) are a powerful tool to create
site-specific genomic modifications in a wide variety of cell
types and organisms and are about to enter human gene
therapy clinical trials. An important aspect of using ZFNs
for use in gene therapy is to minimize off-target effects.
We made ZFNs that contain destabilizing domains on their
amino-terminus. The expression level of the modified ZFNs
could be increased transiently by the addition of a small
molecule, either a proteasome inhibitor or Shield1. We
demonstrate that off-target effects can be reduced
without compromising gene targeting efficiency by using
small molecules to limit the maximal expression of the
ZFNs to a narrow window. The ability to regulate ZFN
expression using small molecules provides a new strategy
to minimizing off-target effects of ZFNs and may be an
important way of ultimately using ZFNs for clinical use in
gene therapy protocols.
Minimizing ZFN Toxicity
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Ub-R-ZFNs examined in this experiment produced lower toxicity
and therefore a higher percentage of survival compared to the
unmodified proteins. At 20 nanograms (ng) of Ub-R-ZFNs in the
presence of drug, there was no observable toxicity in this assay.
This is also the amount at which equivalent rates of gene targeting
were obtained relative to the unmodified proteins (Figure 2D). In
summary, we found that the VV-linked versions minimized
toxicity at the cost of reduced targeting efficiency. In contrast,
using the R-linked versions, we could decrease toxicity without
losing targeting efficiency.
The Destabilization Domain Method as a Strategy to
Regulate ZFN Protein Levels
An alternative strategy to using ubiquitin involves linking a
destabilization domain to the POI. This destabilization domain
was engineered by making mutants of the FKBP12 protein, which
is constitutively and rapidly degraded in mammalian cells [30].
Fusion of this destabilization domain to another protein confers
instability to the fusion protein. In order to stabilize the protein,
Banaszynski et al. (2006), developed a synthetic ligand (called
Shield1) that binds the destabilization domain and protects the
fusion protein from degradation [30].
We made a pair of chimeric proteins that linked the
destabilization domain (dd) to the N-terminus of the ZFNs,
containing the wildtype FokI domain, that target the GFP gene
(‘‘dd-ZFNs’’, Figure 3A). We examined the expression of the dd-
ZFNs and unmodified ZFNs in transfected HEK293 cells by
Western blot analysis (Figure 3B). In the absence of Shield1, the
dd-ZFNs were destabilized as shown by reduced expression
relative to the unmodified ZFNs. Upon addition of Shield1 for the
first 24 hours post transfection, however, the dd-ZFNs were
stabilized to relatively equivalent levels of expression as the
unmodified ZFNs at 24 hours. The amount of protein expressed at
32 hours post transfection after drug treatment, however, was
substantially reduced when compared to the unmodified ZFNs at
the same time point (Figure 3B).
To examine the activity of the dd-ZFNs, we used the GFP gene
targeting assay. At high concentrations of DNA, the rate of gene
targeting stimulated by the dd-ZFNs in the absence of drug almost
reached the rate stimulated by the unmodified ZFNs (Figure 4A).
Because of this high rate of targeting in the absence of drug, we
chose to continue the experiments with 5 or 20 nanograms of
transfected DNA. We conducted a series of experiments to
characterize the timing and dosing of the drug in order to
determine the drug conditions needed to obtain optimal rates of
Figure 1. Characterization of Ub-X-ZFNs that display drug-dependent stability. (A) Genetic fusion of a ubiquitin moiety to a ZFN with
either a ‘‘VV’’ linker or an ‘‘R’’ linker. (B) Expression profile of unmodified and Ub-X-ZFN proteins in the presence and absence of 10 uM of the
proteasome inhibitor MG132 from 18–22 hours post-transfection. HEK293FT cells were transiently transfected with vectors encoding either ZFN-1/
ZFN-2, Ub-VV-ZFN-1/-2, or UB-R-ZFN-1/ZFN-2. ZFNs were detected using Western blot analysis with an anti-Flag antibody. ZFN-1/ZFN-2 and Ub-R-
ZFN-1/ZFN-2 were approximately 37 kD and Ub-VV-ZFN-1/ZFN-2 were approximately 47 kD. The size difference between the Ub-X-ZFNs is due to the
Ub-moiety being cleaved off when linked via an R-linker. b-actin serves as a loading control.
doi:10.1371/journal.pgen.1000376.g001
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PLoS Genetics | www.plosgenetics.org 3 February 2009 | Volume 5 | Issue 2 | e1000376Figure 2. Analysis of Ub-X-ZFNs. Unless otherwise indicated, rates of gene targeting at day 3 were normalized to the rate of gene targeting
achieved using 20 ng of the unmodified ZFNs without drug treatment as this was previously determined to be the conditions used to obtain optimal
gene targeting with the unmodified ZFNs. The absolute rate of gene targeting using ZFN-1/ZFN-2 at 20 ng in HEK293 cells was about 20,000 GFP
positive cells per million cells transfected (about 2%). (A) Titration of transfected DNA of Ub-VV-ZFNs in the gene targeting assay with increasing
amounts of DNA. (B) Titration of transfected DNA of Ub-R-ZFNs in the gene targeting assay with increasing amounts of DNA. (C and D) Gene targeting
in the absence and presence of 10 uM MG132 for given ZFN pairs at stated DNA concentrations. (E) Toxicity assay for all iterations of Ub-modified and
unmodified ZFNs tested in the gene targeting assay relative to Sce. A value of ,100% indicates decreased cell survival as compared with Sce, and
demonstrates a toxic effect. Statistical analysis was performed using the Student’s T-test comparing ZFN-1/ZFN-2 at 20 ng with no drug treatment to
Ub-modified ZFNs treated with MG132. ‘‘*’’ indicates a P-value of ,.05 and ‘‘n.s.’’ indicates no statistical significance or a P-value of ..05. Error bars
are the standard deviation for three samples.
doi:10.1371/journal.pgen.1000376.g002
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gene targeting induced by the dd-ZFNs is equivalent to the rate
stimulated by the unmodified ZFNs (Figure 4B). We found that
additional exposure to the drug, beyond 24 hours, did not further
increase these rates (data not shown).
We next evaluated the dosing of the Shield1 drug with respect
to gene targeting. At 1000 nM of Shield1, we observed equivalent
rates of gene targeting, but there was a dose-dependent decrease in
targeting as the dose was lowered (Figure 4C). With Shield1
present at 1000 nM for the first 24 hours, we observed that using
either 5 or 20 nanograms of the dd-ZFNs could produce rates of
gene targeting equivalent to the optimal rates obtained with the
unmodified ZFNs in HEK293 cells (Figure 4D). To determine if
this method could be used in other cell types, we measured the
gene targeting rates in HeLa and 3T3 cells stably transfected with
the GFP gene targeting system. As shown in Figure 4E and 4F, the
addition of Shield1 to cells transfected with the dd-ZFNs resulted
in an increase in the rate of gene targeting relative to when the
drug was absent. In the presence of Shield1, the rates of gene
targeting in both the 3T3 cells and HeLa cells at 20 ng were
equivalent to the rates produced using the unmodified ZFNs at
20 ng with no drug treatment (Figure 4E and F).
To determine if linking the destabilization domain to the ZFNs
reduced the cytotoxicity associated with the unmodified ZFNs, we
used the toxicity assay. Strikingly, in the presence of drug at 5 or
20 ng of dd-ZFNs, toxicity relative to Sce appears to be negligible,
and there is a significant reduction in toxicity compared to the
unmodified ZFNs at 20 ng (Figure 4G). We found that ZFNs with
a N-terminal FKBP12 domain that is not destabilizing have
greater toxicity than the dd-ZFNs, suggesting that the decreased
toxicity is not simply the result of improved protein folding (data
not shown).
Previous studies have suggested that the cytotoxicity associated
with unmodified ZFNs is due to the creation of off-target DSBs
[16–18]. When a DSB occurs, a signaling cascade is activated
including the phosphorylation of H2AX and the recruitment of an
array of proteins, including 53BP1, to the site of the DSB that can
be detected as foci by immunofluorescence [16,31]. We have
previously shown that ZFNs that produce larger numbers of foci
are more toxic than ZFNs that produce fewer foci [16]. Although
the unmodified ZFN pair used in this study shows cytoxicity in the
toxicity assay, this pair did not show an increased number of foci
per cell relative to Sce when this assay was performed in human
foreskin fibroblasts. To sensitize the assay, we used cells mutated in
Ku80, a gene important in the non-homologous end-joining
pathway of DSB repair, which are known to have delayed repair of
DSBs [32]. In this cell line, GFP transfected cells and cells
transfected with Sce alone had an average of about 4 foci per cell
(Figure 5). As a further control, we transfected cells with a plasmid
encoding Caspase Activated DNAse (CAD), an endonuclease that
cleaves DNA non-specifically. CAD-transfected cells had an
average of about 12 foci per cell (Figure 5). To aid in our
comparison of the unmodified ZFNs and dd-ZFNs, we used higher
amounts of DNA than determined in Figure 3 in order to amplify
the number of DSBs visualized. We did however maintain the 1:4
ratio (5 ng:20 ng vs. 75 ng:300 ng) of dd-ZFN DNA concentration
with respect to unmodified ZFN DNA concentration for this
comparison. Cells transfected with the unmodified ZFNs had an
average of 10 foci per cell (comparable to the CAD transfected
cells, Figure 5B). In contrast, the dd-ZFN transfected cells had only
about 4 foci per cell (comparable to the GFP-alone and Sce
transfected cells). In summary, linking the destabilization domain
of a modified FKBP12 protein to the N-terminus of ZFNs resulted
in a way to regulate the expression level of the ZFNs that
maintained high rates of gene targeting while minimizing toxicity.
Discussion
Homologous recombination is the most precise way to
manipulate the genome and is a powerful experimental tool in
Figure 3. Characterization of dd-ZFNs that display Shield1-dependent stability. (A) Genetic fusion of a destabilization domain derived
from an FKBP12 mutant to a ZFN. (B) Expression profile of unmodified and dd-ZFN proteins in the presence and absence of 1 uM of the Shield1 from
0–24 hours post-transfection. HEK293FT cells were transiently transfected with vectors encoding either ZFN-1/-2, dd-ZFN-1/-2. ZFNs were detected
with an anti-Flag antibody. b-actin serves as a loading control. The molecular weight of the unmodified GFP-ZFNs was approximately 37 kD and for
the dd-ZFNs approximately 50 kD.
doi:10.1371/journal.pgen.1000376.g003
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rate of gene targeting in a wide variety of experimental systems
previously not amenable to genome manipulation by homologous
recombination [2,10,13,17,23,24,33]. In addition to the problem
of designing ZFNs to recognize target sites [34], another limitation
has been concern about off-target effects [2,15–17]. Improvements
in toxicity have been attained by increasing the specificity of ZFNs
and by modifications of the nuclease domain [16,19–24,35].
Further strategies to minimize ZFN toxicity, however, could
further broaden the window between the desired and undesired
genomic effects of ZFNs. In whole organisms such as flies and
zebrafish, high levels of ZFN expression led to abnormal
developmental mutations [18,24,33]. Reducing ZFN toxicity by
regulating ZFN expression could hypothetically help attenuate
these abnormalities. In this work, we show that small molecule
regulation of ZFN expression can result in an improved toxicity
profile without sacrificing gene targeting activity. The use of the
destabilization domain may not be necessary when making gene
modified cell lines (where one can characterize a single clone) but
instead will be useful when treating a large population of cells that
may be infused into a patient (as would be done in gene therapy)
where isolation of a single clone is either not feasible or desirable.
The standard strategy to control protein levels is to use
transcriptional based methods (examples include the TetOn or
TetOff: Clonetech, Ponasterone System; Stratagene, and Dimer-
izer System; Ariad). Gene targeting induced by ZFNs is already a
three-component system (ZFN-1, ZFN-2, and a repair/donor
molecule). Adding an inducible transcriptional regulator as a
fourth component to make the system more complex was not
desirable, particularly as the technology moves into cell types that
are more difficult to transfect or infect. The ERT2 domain, a
modified ligand binding domain from the estrogen receptor, has
been successfully used to control protein activity by modulating the
location of the protein. Unfortunately, we found that attaching the
ERT2 domain to ZFNs did not stimulate gene targeting with
presence of tamoxifen (data not shown). An alternative strategy is
to use a post-translational method of regulating ZFN level. In this
strategy, a destabilized ZFN is created by adding a destabilizing
domain and then levels of ZFNs are controlled by adding a small
molecule to block the destabilization effects. By fusing a ubiquitin
domain to the N-terminus through a non-cleavable linker (Ub-
VV-ZFN), we made ZFNs that could be regulated by proteasome
inhibition, which resulted in decreased toxicity. When we fused the
ubiquitin domain to the N-terminus of the ZFN through a
cleavable linker leaving a destabilizing arginine at the N-terminus,
we created ZFNs that were regulated by proteasome inhibition
resulting in decreased toxicity and maintained high rates of gene
targeting. Because proteasome inhibitors such as bortezomib are
FDA approved for use in humans, this strategy has long-term
promise. We did find the window of exposure to MG132, the
proteasome inhibitor used in this study, in which we got good
induction without cytotoxicity was narrow. Finally, when we fused
a modified FKBP12 domain to the N-terminus of the ZFN, we
created ZFNs that were regulated by the small molecule Shield1,
which resulted in reduced ZFN toxicity and maintained high rates
of targeting. Despite using amounts of Shield1 for prolonged
periods (up to 48 hours), we did not observe any discernable
toxicity. Moreover, by expression microarray analysis, Shield-1
has almost no effect on gene expression [36]. Thus, the Shield1/
FKBP12 system may ultimately be the better system despite
Shield1 not being currently FDA approved for use in humans.
Regulating ZFN expression also gave insight into the kinetics of
gene targeting. Previously, Porteus and Baltimore found that
maximal gene targeting was measured at 60 hours after transfec-
tion [2]. In this work, we demonstrate that ZFNs need only be
expressed for less than 32 hours after transfection to attain
maximal gene targeting (measured at 72 hours post-transfection).
These experiments define a window for ZFN expression, here
defined as 0–32 hours but perhaps even shorter, in which
expression of ZFNs beyond the window does not increase targeting
but does increase toxicity. We have no explanation for the 32-hour
window for gene targeting based on experimental data. One would
expect, for example, that gene targeting events should increase as
long as ZFNs are present, but we do not observe this [2]. A
hypothesis is that the repair substrate/donor may not be available
(for example dilution, sequestration, or modification) for the repair
of a double strand break by homologous recombination after this
window. This hypothesis will have to be experimentally tested in
the future.
Previously, we used human diploid fibroblasts to measure
53BP1 foci created by off-target DSBs. The unmodified ZFNs
used in this study did not show significantly increased numbers of
foci in that cell line, presumably because the cells were efficient at
repairing DSBs. To sensitize the assay, we used murine Ku80
2/2
cells that are deficient in DSB repair. Using these sensitized cells
resulted in a higher number of background 53BP1 foci, but also
allowed us to detect subtle differences in ZFN toxicity between dd-
ZFNs and untagged ZFNs that we could not detect using cells that
were not deficient in DSB repair. As ZFNs continue to improve,
the use of sensitized assays to quantitate improvements will be an
important strategy.
We have utilized strategies in which a drug stabilizes the protein
rather than a drug to destabilize the protein. This ‘‘drug-on’’
system has several advantages. First, it means that the drug only
needs to be administered for a brief period (the window to
maximize gene targeting activity). This brief administration is
Figure 4. Analysis of dd-ZFNs. Unless otherwise indicated, rates of gene targeting at day 3 were normalized to the rate of gene targeting
achieved using 20 ng of the unmodified ZFNs without drug treatment as this was previously determined to be the conditions used to obtain optimal
gene targeting with the unmodified ZFNs. The absolute rate of gene targeting using ZFN-1/ZFN-2 at 20 ng in HEK293 cells was about 20,000 GFP
positive cells per million cells transfected. (A) Titration of transfected DNA of dd-ZFNs in the gene targeting assay with increasing amounts of
transfected DNA. (B) Time-course experiment for length of exposure of 1000 nM Shield1 using 5 ng of dd-ZFNs. Hours are given relative to the time
of transfection, where ‘‘0’’ is the time of transfection. (C) Drug dose response curve for Shield1 with 5 ng of dd-ZFNs. (D) Gene targeting in the
absence and presence of 1000 nM Shield1 for given ZFN pairs at stated DNA concentrations in HEK293 cells. (E) Gene targeting in the absence and
presence of 1000 nM Shield1 for given ZFN pairs at stated DNA concentrations in 3T3 cells. The absolute rate of gene targeting using ZFN-1/ZFN-2 at
20 ng in 3T3 cells was about 20,000 GFP positive cells per million cells transfected (2%). (F) Gene targeting in the absence and presence of 1000 nM
Shield1 for given ZFN pairs at stated DNA concentrations in HeLa cells per million cells transfected. The absolute rate of gene targeting using ZFN-1/
ZFN-2 at 20 ng in HeLa cells was about 2,000 GFP positive cells per million cells transfected (0.2%). (G) Toxicity assay for all iterations of dd-modified
and unmodified ZFNs tested in the gene targeting assay relative to Sce. A value of ,100% indicates decreased cell survival as compared with Sce,
and demonstrates a toxic effect. Statistical analysis was performed using the Student’s T-test comparing ZFN-1/ZFN-2 at 20 ng with no drug
treatment to dd-modified ZFNs treated with Shield1. ‘‘*’’ indicates a P-value of ,.05 and ‘‘n.s.’’ indicates no statistical significance or a P-value of ..05.
Error bars are the standard deviation in measurement of three samples.
doi:10.1371/journal.pgen.1000376.g004
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PLoS Genetics | www.plosgenetics.org 7 February 2009 | Volume 5 | Issue 2 | e1000376Figure 5. Visualization of ZFN-induced DSBs by sensitized 53BP1 foci formation assay. (A) Representative cells for each experimental
condition after 53BP1 staining using indicated amounts of transfected DNA of each nuclease in the presence or absence of drug. 53BP1 foci are seen
in red, 4,6-diamidino-2-phenylindole staining in blue, and GFP-positive cells in green. The foci were counted in transfected cells that were GFP-
positive. ‘‘Untransfected’’ shows the background staining for foci in these cells, GFP indicates transfection of GFP alone, Sce serves as a negative
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potential side-effects of the drug itself. Second, when the drug is
absent, the ground state of ZFN expression will be low, thus
reducing the potential side-effects of the ZFNs.
In summary, we have found that small molecule regulation of
ZFN expression is an effective way to reduce cytotoxicity without
compromising targeting efficiency. This strategy may be particu-
larly beneficial to using ZFN mediated genome modification in a
wide variety of cell types, including human stem cells.
Materials and Methods
DNA Manipulations and Cloning
All plasmids were made using standard cloning techniques and
molecular biology as previously described [37]. The unmodified
ZFNs were selected by the B2H design strategy and fused to the
wildtype FokI nuclease domain as described earlier and called
‘‘GFP1.4-B2H’’ and ‘‘GFP2-B2H’’ [16]. For the Ub-X-ZFN
versions, the ubiquitin open reading frame was amplified by PCR
from pUb-R-GFP [28] with sense primer 59-ACTGGGATCCTC-




AC-39 for the Ub-R-ZFNs (restriction site underlined, variable
codons inbold) and cloned into the ZFN expression plasmid using the
BamHI site. Directionality was determined by XbaI digest. To create
the dd-ZFNs, the L106P destabilization domain was PCR amplified
using primers 59-ACGTGCGGCCGCACCATGGGAGTGCAG-
GTGGAAACCATCTCC – 39 and 59-ACTGGGATCC-
TTCCGGTTTTAGAAGCTCCAC-39. The resulting fragment
was digested with NotI and BamHI and cloned in-frame to the N-
terminus of the GFP-ZFNs in a CMV expression vector. For all
constructs the N-terminal domains and junctions were confirmed by
sequencing.
Cell Culture and Transfection
All cell culture experiments were performed in HEK293 cells
except where identified. Cells were cultured in a humidified
incubator at 37uC with 5% CO2 in DMEM supplemented with
10% bovine growth serum (Hyclone, Logan, UT, USA), 2 mM L-
glutamine, 100 IU/ml penicillin, and 100 mg/ml streptomycin.
Stable cell lines were constructed as previously described [15].
Transient transfections were performed using the calcium
phosphate technique as previously described and produced
transfection efficiencies between 10–35% [38].
Proteasome Inhibitor
For experiments using MG132 (carboxybenzyl-leucyl-leucyl-
leucinal; Sigma-Aldrich, St. Louis, MO),10 uM drug was added to
cells from 18–22 hours post-transfection unless otherwise noted.
We determined this window and concentration of the proteasome
inhibitor empirically to maximize stimulation of gene targeting
while minimizing toxic effects of the drug (data not shown).
Shield1
For experiments using Shield1 (Clontech, Mountain View, CA),
1000 nM drug was added to cells from time of transfection and left
on for 24 hours unless otherwise noted. As discussed in the results,
we determined the dose and timing of the drug empirically to
maximize gene targeting activity and minimizing toxicity.
Measurement of Gene Targeting using the GFP System in
HEK293 Cells
Gene targeting experiments were performed in triplicate as
previously described using calcium phosphate transfection [15].
Transfection efficiencies were determined at day 2 post-transfec-
tion, and the rates of gene targeting were determined by flow-
cytometry and analyzed on a FACS Calibur (Becton-Dickinson,
San Jose, CA, USA) at day 3 (day of transfection is considered day
0). Gene targeting rates are calculated as GFP positive cells per
million cells transfected because the background rate of sponta-
neous gene targeting using this system is approximately one event
per million cells. Gene targeting rates are then normalized to the
percent gene targeting obtained using 20 ng of ZFN-1 and ZFN-2
as these conditions have given the highest rates of gene targeting
for the unmodified proteins. The absolute rate of gene targeting
using ZFN-1/ZFN-2 at 20 ng in HEK293 cells was about 20,000
GFP positive cells per million cells transfected.
Measurement of Gene Targeting using the GFP System in
HeLa and 3T3 Cells
Both a HeLa and 3T3 cell line were created using electropo-
ration that stably incorporated the GFP gene targeting system.
Gene targeting experiments were performed in triplicate as
previously described [15]. Lipofectamine 2000 Reagent (Invitro-
gen) was used to transfect cells using Invitrogen’s suggested
protocol. pcDNA6/V5-HisA plasmid DNA was added as stuffer
DNA when necessary to raise the total DNA to 800 ng per well.
1000 nM Shield1 was added to drug-treated wells at the time of
transfection. 24 hours later, Shield1 was removed and the medium
was replaced with fresh, supplemented Dulbecco’s Modified
Eagle’s Medium. The absolute rate of gene targeting using ZFN-
1/ZFN-2 at 20 ng in HeLa cells stably transfected with GFP gene
targeting reporter was about 2,000. The absolute rate of gene
targeting using ZFN-1/ZFN-2 at 20 ng in 3T3 cells stably
transfected with the GFP gene targeting reporter was about
20,000.
Immunodetection of ZFNs
For time course blots, cells were harvested at indicated times
post-transfection. Each sample was counted and lysate volumes
were adjusted to give equal amounts of cells per volume. Equal
amounts of total lysates were subjected to SDS-PAGE, wet
transferred to PVDF membranes and incubated with specific
antibodies. ZFNs were detected using an anti-Flag M2 monoclonal
antibody (1:10,000, Sigma-Aldrich), and b-actin was detected
using a rabbit anti-actin antibody (1:5,000, Sigma-Aldrich). The
blots were further incubated with HRP-conjugated secondary
antibodies and visualized using Western blotting luminal reagent
(Santa Cruz Biotechnology, Santa Cruz, CA).
Flow Cytometry-Based Assay for Cell survival: ‘‘Toxicity
Assay’’
Toxicity assays were performed as previously described [16].
Briefly, HEK293 cells were transfected in triplicate by calcium
phosphate technique with 200 ng of a GFP expression plasmid
control for ZFN-induced foci formation, and Caspase Activated DNAse (CAD) serves as a positive control for 53BP1 foci formation. ((2)) indicates no
Shield1 treatment and ((+)) indicates 1000 nM Shield1 treatment for 24 hours after transfection. (B) The average number of 53BP1 foci per transfected
cell in Ku80
2/2 murine 3T3 cells for each experimental condition in (A).
doi:10.1371/journal.pgen.1000376.g005
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(two plasmids total). At day two post-transfection, a fraction of
transfected cells was analyzed by flow-cytometry and the
percentage of GFP positive cells was determined. At day six
post-transfection, the percentage of GFP positive cells was
determined by flow-cytometry. To calculate the percent survival
relative to Sce, a ratio of ratios was calculated as previously
described [16]. The ratio after nuclease transfection was
normalized to the ratio after Sce transfection and this determined
the percent survival compared to Sce. In control experiments, we
showed that Sce expression had no effect on cell survival
compared to cells transfected with an empty expression vector.
Sensitized 53BP1 Foci Formation Assay
Cell Culture: Ku80
2/2 mouse 3T3 cells were maintained in
Dulbecco’s Modified Eagle’s Medium (Hyclone, Logan, UT)
supplemented with 20% fetal calf serum and 2 mmol/l L-
glutamine. The cells were maintained in a humidified incubator
with 5% CO2 at 37uC.
Transfection of 3T3 Ku80
2/2 cell line: Mouse 3T3 cells that
are Ku80
2/2 were used in these studies because they repair DNA
breaks more slowly, providing a more sensitive assay for
monitoring DNA damage. Ku80
2/2 cells were seeded in 4-well
Lab-Tek II Chamber Slides (Nalge Nunc, Rochester, NY) at
40,000 cells per well. 24 hours later, cells in each well were
lipofected with 200 ng GFP DNA and 75 ng or 300 ng of each
nuclease. pcDNA6/V5-HisA plasmid DNA was added as stuffer
DNA when necessary to raise the total DNA to 800 ng per well.
Lipofectamine 2000 Reagent (Invitrogen) was used to transfect
cells using Invitrogen’s suggested protocol. 1000 nM Shield1 was
added to drug-treated wells at the time of transfection. 24 hours
later, Shield1 was removed and the medium was replaced with
fresh, supplemented Dulbecco’s Modified Eagle’s Medium.
48 hours after lipofection the cells were fixed, stained and
visualized. 53BP1 foci were counted only in cells that were
brightly GFP positive because these were the ones transfected with
the GFP and the nuclease(s).
Immunofluorescence Staining
Immunofluorescence staining was carried out as performed in
[16]. Briefly, cells were washed in phosphate buffered saline, fixed
in cold 4% paraformaldehyde, washed again, and then permea-
bilized with .5% Triton X-100. Cells were re-washed, blocked in
5% bovine serum albumin, and then incubated with rabbit anti-
53BP1 antibody (Cell Signaling, Danvers, MA). After another set
of washes, cells were incubated with goat anti-rabbit Rhodamine
Red-X antibody (Invitrogen, Carlsbad, CA). Cells were washed
again and then mounted in Vectashield mounting medium
containing 4,6-diamidino-2-phenylinodole (Vector Laboratories,
Burlingame, CA). Images were captures using an epifluorescence
microscope equipped with a Q-Fire charge-coupled device camera
(Olympus America, Melville, NY) and QCapture Software
(QImaging, British Columbia, Canada). Images were merged
using ImageJ Software (NIH, ver. 1.40 g).
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